troubles hépatiques et biliaires
Lésions hépatiques provoquées par les médicaments
Références générales
1.Athyros VG, Tziomalos K, Gossios TD, et al: Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A post-hoc analysis.Lancet376(9756):1916-1922, 2010. doi: 10.1016/S0140-6736(10)61272-X 2.Tikkanen MJ, Fayyad R, Faergeman O, et al: Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.Int J Cardiol168(4):3846-3852, 2013. doi: 10.1016/j.ijcard.2013.06.024 3.Fontana RJ, Liou I, Reuben A, et al: AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury.Hepatology00:1-29, 2022. doi: 10.1002/hep.32689 4.Chalasani N, Bonkovsky HL, Fontana R, et al: Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study.Gastroenterology148(7):1340-1352, 2015. doi: 10.1053/j.gastro.2015.03.006 5.Navarro VJ, Barnhart H, Bonkovsky HL, et al: Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network.Hepatology60(4):1399-1408, 2014. doi: 10.1002/hep.27317 